Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 7/20 | 0.64 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | FBP1 | P09467 | 1/20 | 0.46 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | NQO2 | P16083 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2173475 | 1.00 | NFE2L2 (0.64) | NFE2L2HSD11B1APPPTGS1FBP1 | |
| SCHEMBL11211999 | 0.85 | MAOB (0.42) | NFE2L2APPALDH1A1LMNATRPA1 | |
| SCHEMBL11212004 | 0.85 | MAOB (0.42) | NFE2L2APPALDH1A1LMNATRPA1 | |
| SCHEMBL11209918 | 0.85 | MAOB (0.42) | NFE2L2APPALDH1A1LMNATRPA1 | |
| SCHEMBL700051 | 0.82 | NFE2L2 (0.78) | NFE2L2HSD11B1APPPTGS1FBP1 | |
| SCHEMBL700052 | 0.82 | NFE2L2 (0.78) | NFE2L2HSD11B1APPPTGS1FBP1 | |
| SCHEMBL22468800 | 0.82 | NFE2L2 (0.78) | NFE2L2HSD11B1APPPTGS1FBP1 | |
| SCHEMBL13766558 | 0.82 | NFE2L2 (0.78) | NFE2L2HSD11B1APPPTGS1FBP1 | |
| SCHEMBL13766470 | 0.82 | NFE2L2 (0.78) | NFE2L2HSD11B1APPPTGS1FBP1 | |
| SCHEMBL4946969 | 0.78 | NFE2L2 (1.00) | NFE2L2APPPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113511972-B | (E) Process for preparing (E) -4-aryl-2, 2-difluoro-3-butenoic acid derivatives | 昆明理工大学 | 2025-01-21 | — | — | CN | disclosed |
| CN-115160101-A | Synthetic method of (R) -1, 3-diaryl butene compound | 南京工业大学 | 2022-10-11 | — | — | CN | disclosed |
| US-9458155-B2 | Pyrido[4,3-b]indoles containing rigid moieties | MEDIVATION TECHNOLOGIES, INC (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150051218-A1 | PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES | MEDIVATION TECHNOLOGIES, INC. | 2015-02-19 | — | — | US | disclosed |
| US-8907097-B2 | Pyrido[4,3-b]indoles containing rigid moieties | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-8906925-B2 | Pyrido[4,3-B]indoles containing rigid moieties | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20130190322-A1 | PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| EP-2346332-A1 | PYRIDO (4,3-B) INDOLES CONTAINING RIGID MOIETIES | Medivation Technologies, Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20100216814-A1 | PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES | MEDIVATION TECHNOLOGIES, INC. | 2010-08-26 | — | — | US | disclosed |
| WO-2010051501-A1 | PYRIDO (4,3-B) INDOLES CONTAINING RIGID MOIETIES | MEDIVATION TECHNOLOGIES, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
| US-4038273-A | Piperidone intermediates useful in the preparation of aryldecahydropyrrolo [3,4-f]quinolines | E. R. SQUIBB & SONS, INC. (US) | 1977-07-26 | — | — | US | disclosed |
| US-3963724-A | Intermediates useful in the preparation of aryldecahydropyrrolo[3,4-f]quinolines | E. R. SQUIBB & SONS, INC. (US) | 1976-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051218-A1 | PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES | HTR3B, HTR3D, HTR3A | NFE2L2 2298/4885HSD11B1 2950/4885APP 143/4885 |
| US-20130190322-A1 | PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES | HTR3B, HTR3D, HTR3A | NFE2L2 2298/4885HSD11B1 2950/4885APP 143/4885 |
| US-20100216814-A1 | PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES | HTR3B, HTR3D, HTR3A | NFE2L2 2298/4885HSD11B1 2950/4885APP 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.